Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life. The treatment landscape for chronic lymphocytic leukemia (CLL) has undergone a seismic shift, moving from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results